image credit: Pexels

Overcoming the challenges of developing vaccines in an accelerated timeframe

The world responded to the crisis at unprecedented speed, as leaders and experts focused on different ways to operate and succeed within the constraints of a new dynamic. One standout success we have all benefitted from is vaccine development, with notable vaccines from Pfizer/BioNTech, AstraZeneca, and Moderna.

As the world stopped, researchers and stakeholders from across the industry turned their attention to tackling the SARS-CoV-2 virus. But despite this focus, new challenges were ubiquitous. COVID-19 set new expectations for how quickly R&D can move; the Coalition for Epidemic Preparedness Innovations (CEPI) has since established a 100 Days Mission for responding to the next Disease X, but what needs to happen for this to become a reality?

Read More on Pharmaphorum